Long-Term Efficacy of Adjunctive Cariprazine in Patients With MDD: Results From an Open-Label 26-Week Safety Study

被引：0
|
作者：
Masand, Prakash [1 ]
Vieta, Eduard [1 ]
Waraich, Simranpreet [1 ]
Kramer, Ken [1 ]
Kerolous, Majid [1 ]
机构：
[1] AbbVie, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
Cariprazine; Major Depressive Disorder; Depression; Adjunctive; Long-Term;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P343
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [31] Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study
    Kwon, Jun Soo
    Jang, Joon Hwan
    Kang, Do-Hyung
    Yoo, So Young
    Kim, Yong Ku
    Cho, Seong-Jin
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2009, 63 (01) : 73 - 81
  • [32] Long-term efficacy and safety with zonisamide: Interim analysis of an open-label study
    Wroe, S
    Brodie, MJ
    EPILEPSIA, 2005, 46 : 118 - 118
  • [33] Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial
    Lagae, Lieven
    Klotz, Kerstin Alexandra
    Fogarasi, Andras
    Floricel, Florin
    Reichel, Christoph
    Elshoff, Jan-Peer
    Fleyshman, Sofia
    Kang, Harriet
    EPILEPSIA, 2023, 64 (11) : 2934 - 2946
  • [34] Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study
    Lepola, Ulla
    Hefting, Nanco
    Zhang, Doris
    Hobart, Mary
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (10) : 1403 - 1410
  • [35] Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial
    Cutler, Andrew J.
    Kalali, Amir H.
    Mattingly, Greg W.
    Kunovac, Jelena
    Meng, Xiangyi
    CNS SPECTRUMS, 2013, 18 (01) : 43 - 54
  • [36] Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer's Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan
    Homma, Akira
    Imai, Yukimichi
    Tago, Hisao
    Asada, Takashi
    Shigeta, Masahiro
    Iwamoto, Toshihiko
    Takita, Masashi
    Arimoto, Itaru
    Koma, Hiroshi
    Takase, Takao
    Ohbayashi, Toshio
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 27 (03) : 232 - 239
  • [37] Long term effects of rivastigmine in patients with traumatic brain injury with cognitive deficits: Results of a 26-week open-label extension to a 12-week double-blind study
    Gunay, Ibrahim
    Koumaras, Barbara
    Silver, Jonathan
    ANNALS OF NEUROLOGY, 2006, 60 : S62 - S62
  • [38] Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
    Goemans, Nathalie M.
    Tulinius, Mar
    van den Hauwe, Marleen
    Kroksmark, Anna-Karin
    Buyse, Gunnar
    Wilson, Rosamund J.
    van Deutekom, Judith C.
    de Kimpe, Sjef J.
    Lourbakos, Afrodite
    Campion, Giles
    PLOS ONE, 2016, 11 (09):
  • [39] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
  • [40] Long-Term Efficacy of Lacosamide as Adjunctive Therapy in Patients with Uncontrolled POS: Results from a Phase III Open-Label Extension Trial
    Chung, Steve
    Faught, Raymond Edward
    Husain, Aatif
    Isojarvi, Jouko
    Doty, Pamela
    NEUROLOGY, 2011, 76 (09) : A376 - A376
12345